---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-004236"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:26:49.366099+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Moleculin gets Japanese patent allowance for Annamycin reconstitution methods

## Summary
- Japan Patent Office issued notice of allowance for Patent App. 2021-577862 covering liposomal Annamycin preparation methods.
- Patent expected to issue in coming months; complements existing US and European Annamycin patents.
- Annamycin (naxtarubicin) is in Phase 3 for relapsed/refractory AML with FDA Fast Track and Orphan Drug designations.
- CEO Klemp states the allowance strengthens international IP for non-cardiotoxic anthracycline therapy.
- Additional Annamycin-related patent applications are pending in major jurisdictions worldwide.

## SEC filing metadata
- accession: 0001437749-26-004236
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926004236/0001437749-26-004236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926004236/mbrx20260216_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-004236
- JSON: https://secwatch.observer/filing/0001437749-26-004236.json
- Plain text: https://secwatch.observer/filing/0001437749-26-004236.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.